Kazia Therapeutics (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, today announced compelling preclinical and translational data ...

Cancer immunotherapy has been a game-changer, but many tumors still find ways to slip past the immune system. New research ...

The Sydney-based oncology company revealed that NDL2 is designed to eliminate nuclear PD-L1, which Kazia identified as a ...

Cancer immunotherapy has transformed modern oncology by harnessing body's own immune system to combat malignant disease.

Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression SYDNEY, Jan. 30, 2026 /PRNewswire/ -- Kazia ...

The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology to include ...

Kazia stated that in murine triple-negative breast cancer preclinical models, NDL2 reduced primary tumor volume by 49% as ...

Cancer immunotherapy has transformed modern oncology by harnessing the body's own immune system to combat malignant disease.

These innovative biotechs could have plenty of upside ahead.

Colorectal cancer, the abnormal growth of cancerous cells in the large intestine or the rectum, is one of the most common ...

CheckMate 9LA showed a 26% overall survival benefit for metastatic NSCLC patients treated with nivolumab and ipilimumab plus chemotherapy over six years. The combination therapy was particularly ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results ...